Roche’s Columvi (glofitamab) Receives Health Canada Authorization for the Treatment of Adult Patients with Diffuse Large B-cell Lymphoma
- Health Canada has authorized Columvi for the treatment of adult patients with r/r DLBCL who have received two or more lines of systemic therapy
- The authorization was based on the P-I/II multi-cohort trial (NP30179) evaluating Columvi as monotx. which demonstrated that the therapy induced durable response rates in people with heavily pre-treated large B-cell lymphoma. In the single-arm DLBCL cohort, 84.3% of patients were refractory to their most recent therapy, 34.3% received prior CAR T-cell therapy, 35.2% & 50.0% achieved a CR & objective response
- Columvi is a bispecific mAb that binds monovalently to CD3 in the T-cell receptor complex expressed on the surface of T cells & bivalently to CD20 expressed on the surface of B cells
Ref: Roche Canada | Image: columvi®-glofitamab
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.